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Abstract The aim of this article was to perform a sys-
tematic review on the role of melatonin in the prevention of
cancer tumorigenesis—in vivo and in vitro—as well as in
the management of cancer correlates, such as sleep-wake
and mood disturbances. The International Agency for
Research on Cancer recently classified ‘‘shift-work that
involves circadian disruption’’ as ‘‘probably carcinogenic
to humans’’ (Group 2A) based on ‘‘limited evidence in
humans for the carcinogenicity of shift-work that involves
night-work’’, and ‘‘sufficient evidence in experimental
animals for the carcinogenicity of light during the daily
dark period (biological night)’’. The clinical implications
and the potential uses of melatonin in terms of biologic
clock influence (e.g. sleep and mood), immune function,
cancer initiation and growth, as well as the correlation
between melatonin levels and cancer risk, are hereinafter
recorded and summarized. Additionally, this paper
includes a description of the newly discovered effects that
melatonin has on the management of sleep-wake and mood
disturbances as well as with regard to cancer patients’ life
quality. In cancer patients depression and insomnia are
frequent and serious comorbid conditions which definitely
require a special attention. The data presented in this
review encourage the performance of new clinical trials to
investigate the possible use of melatonin in cancer patients
suffering from sleep-wake and mood disturbances, also
considering that melatonin registered a low toxicity in
cancer patients.
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Methods
In this article we aim at systematically reviewing the state
of the art on the role of melatonin in the prevention of
cancer tumorigenesis—in vivo and in vitro—as well as in
the management of cancer correlates, such as sleep-wake
and mood disturbances. In terms of search strategy, English
written articles were sourced in September 2012 by means
of PubMed (no date restriction) using the keywords here-
inafter specified at the beginning of each chapter. More-
over, reasons and criteria based on which the reported
scientific articles have been selected are also specified.
The circadian hormone melatonin and its main function
This research has been carried out based on the keywords:
‘‘melatonin’’ AND ‘‘function’’ AND ‘‘circadian’’; 5,608
articles were sourced. Among them, classical references
have been selected and discussed.
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone
produced at night in the corpus pineale according to a
rhythmical pattern and is controlled by an endogenous clock
located in the hypothalamic suprachiasmatic nucleus [1].
Although it is primarily produced by the pineal gland, a
number of other areas, such as the gut, retina, skin, and
leukocytes [2, 3] also produce Melatonin.
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Its main function is to synchronize the circadian rhythm,
which means the pineal hormone melatonin (N-acetyl-5-
methoxytryptamine) actually acts as a neuroendocrine
transducer of the light–dark cycle [1].
Thanks to its action, melatonin has been tested as a
treatment for a wide range of sleep disorders, including jet
lag, shift-work, primary insomnia, sleep-wake cycle dis-
ruption as well as sleep problems in both children and
elderly suffering from neurodevelopmental disorders [4–6].
The relationship between melatonin and sleep was ini-
tially investigated after registering in humans a higher level
of circulating melatonin at night; furthermore, it was also
noticed that the highest urinary 6-sulphatoxymelatonin
excretion was actually coinciding with the highest noctur-
nal sleepiness [7]. In addition it has to be mentioned that, at
physiologic doses, melatonin also induces sleep onset and
maintenance, decreases sleep latency, improves sleep effi-
ciency and overall increases the total sleep time [8, 9].
Melatonin seems also to be successful in the treatment
of some aging-associated processes, such as disturbances
of sleep/wake rhythm, since the endogenous production of
indoleamine actually decreases with age.
Melatonin is mostly known as a circadian hormone,
although it also prescribed as its sedative [10, 11], anxio-
lytic [10, 11], analgesic [12, 13], antihypertensive [14, 15],
non-inflammatory [16], and oncostatic effects [17–19].
In particular, melatonin seems to produce a possible
antidepressant effect [20, 21]—probably due to the action it
performs on the central circadian regulation [22]—and also
to improve cognitive functions [23, 24].
Disturbances in the rhythm and amplitude of melatonin
secretion may account for symptomatic disturbances to
sleep and mood. Moreover, the close association between
sleep and mood disorders also suggests that melatonin may
play an important role in mood management [25, 26].
Melatonin treatment not only improved total sleep time,
but also reduced depressive symptoms [20, 26–28], thus
indicating a correlation between sleep disturbance and
depression.
Melatonin secretion in cancer patients: what happens?
This research has been carried out based on the keywords:
‘‘melatonin’’ AND ‘‘secretion’’ AND ‘‘cancer’’; 248 arti-
cles were sourced. Among them, the most significant epi-
demiological and retrospective, case–control studies have
been selected and discussed.
In patients suffering from breast, endometrial, or colo-
rectal cancer [29] melatonin secretion is impaired. The
increased incidence of breast and colorectal cancer
observed in nurses and other night-shift workers suggests a
possible correlation between the reduced melatonin secre-
tion and their increased light exposure at night [30, 31].
The physiological surge of melatonin at night is thus
considered a ‘‘natural restraint’’ on tumor initiation, pro-
motion, and progression.
The International Agency for Research on Cancer
(IARC) recently classified ‘‘shift work that involves cir-
cadian disruption’’ as ‘‘probably carcinogenic to humans’’
(Group 2A) on the basis of ‘‘limited evidence in humans
for the carcinogenicity of shift-work that involves night
work’’, and ‘‘sufficient evidence in experimental animals
for the carcinogenicity of light during the daily dark period
(biological night)’’ [32].
The epidemiologic evidence of a relationship between
shift and night work and breast cancer in women is based
upon nine different studies, six of which suggest a mod-
erately increased risk to develop breast cancer after pro-
longed exposure to shift and night work [33]. The possible
physio-pathological mechanisms actually relate to the
internal disruption of biological circadian rhythms and
clock genes, melatonin suppression through light by night,
sleep deprivation.
Among the above-mentioned retrospective case–control
studies, several of them registered in the blood and/or urine
of patients suffering from breast cancer a lower melatonin
or melatonin metabolite concentrations compared with
breast cancer–free women [34–37]. In particular, a study
[36] on the correlation between main melatonin metabolite
excretion and plasma melatonin suggested that the lower
levels registered in breast cancer patients were due to the
lower pineal gland hormone secretion, rather than to an
increase in peripheral metabolism. One of the earlier
studies considered [38] also found nighttime plasma mel-
atonin levels to be lower in estrogen receptor–positive
breast cancer patients compared with estrogen receptor–
negative breast cancer patients as well as healthy control
women. However, other case–control studies registered a
higher daytime serum melatonin concentration in breast
cancer patients compared with healthy control subjects [39,
40], thus assuming that there is no correlation between
breast cancer risk and the mean daytime nadir and night-
time peak plasma concentrations [41]; in addition, the
amount of 6-sulfatoxymelatonin excreted in 24-hour urine
samples turned to be similar both in women suffering from
malignant tumors and in women suffering from benign
breast disease [42]. It is difficult to relate such findings to
both breast cancer patients and breast cancer–free control
subjects, since a series of factors—such as the disease
itself, treatment, and/or behavioral changes—which might
occur after the diagnosis or before surgery/treatment may
actually affect melatonin blood levels. Indeed, several
studies found melatonin secretion to be positively or neg-
atively associated with the severity of the disease in terms
of tumor size [37], depending on whether the cancer has
metastasized [43], as well as whether the patients suffered
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from primary or secondary tumors or not [36]. It is to be
said, however, that such studies were performed on a rather
limited sample, and some of them did not even include
adequate steps to exclude potential confounding effects
relating to age, parity, medication use, or body mass index.
Melatonin levels and cancer risk
This research has been carried out based on the keywords:
‘‘melatonin’’ AND ‘‘secretion’’ AND ‘‘cancer’’; 45 articles
were sourced. Among them, the most significant epidemi-
ological and retrospective, case–control studies have been
selected and discussed.
Epidemiological studies investigated the role of circa-
dian disruption and cancer risk—breast cancer risk in
particular—based upon both direct (urinary melatonin
levels) and indirect measurements, including sleep duration
and shift work. Melatonin production may be closely
related to sleep duration, whereas night-shift work is
expected to disrupt sleep pattern and thus decrease mela-
tonin levels [44, 45]. To date, epidemiological studies
based on direct and indirect melatonin measurements have
been carried out upon Western and Asian populations [46]
with suggestive results [47, 48]. Breast cancer risk was
significantly and inversely associated with urinary mela-
tonin levels (6-sulfatoxymelatonin) in the Nurses’ Health
Study II [49], but not in the United Kingdom Guernsey
Cohort [50]. Breast cancer risk also resulted to be signifi-
cantly reduced in association with long sleep duration in
Finnish women [51], but not in US women [52, 53].
Results from three different cohort studies [54–56] as well
as from two [30, 57] out of three case–control studies [30,
58] also show higher breast cancer risk in women who
usually work at evening or in overnight-shifts.
An Italian case–control study nested within the ORDET
cohort assessed the concentration of melatonin’s major
metabolite, 6-sulfatoxymelatonin (aMT6s), in 178 post-
menopausal women with incident invasive breast cancer as
well as in 710 matched controls. The multivariate relative
risk for women in the highest quartile of total overnight
aMT6s output, compared with the lowest, was 0.56 (95 %
CI, 0.33–0.97). In this report, overnight urinary aMT6s
level and breast cancer risk resulted to be more strongly
associated in women who were diagnosed with invasive
breast cancer more than 4 years after urine collection (OR
0.34 highest versus lowest quartile, 95 % CI, 0.15–0.75)
[59]. In a recent study, the same authors observed a posi-
tive correlation between aMT6s and breast cancer risk [60].
Overall, present studies a correlation between night-shift
work and breast cancer development in Western countries,
as reported by Leonardi et al. [61] in her recent review.
Table 1 summarizes the studies investigating the correla-
tion between melatonin levels and cancer risk. Further
studies are, however, needed to confirm such a correlation
as well as to detect the biomolecular mechanisms which
may be involved in the pathogenesis of cancer diagnosed in
with night-shift workers.
Melatonin, sleep-wake, and mood disturbances
in cancer
This research has been carried out based on the keywords:
‘‘melatonin’’ AND ‘‘cancer’’ AND ‘‘insomnia’’ OR
‘‘sleep’’; 99 articles were sourced. Between these, studies
with the greatest number of patients has been selected and
discussed.
In cancer patients, depression and its correlated disor-
ders stand for a frequent and severe comorbid condition
which may require a special attention [62]. In such patients
the prevalence of major depression ranges from 6 to 42 %,
whereas based on the 31 reports available, the estimated
prevalence rate of depression is 10.8 % [63]. This depends
on various cancer-related variables, such as pain and low-
performance status, as well as risks for major depression.
To avoid the risk of under-diagnosing depression, cancer
patients should undergo an accurate psychological assess-
ment, combined with a careful analysis of concomitant
physical symptoms, such as anxiety, fatigue, cognitive
dysfunction, and sleep disturbances [64–69].
When depression complicates medical conditions, this is
usually associated with a substantially reduced quality of
life (QOL) [70]. Patients also experience increased symp-
tom burden and greater disability and are less likely to
adhere to medical treatments [71].
Although depression is common in cancer patients, this
is frequently undetected and untreated, so despite high
prevalence of depression, studies on effective pharmaco-
therapy are relatively scarce and in particular are burdened
by a high number of dropouts, due to the side-effects re-
latingto the use of antidepressants vs placebo [72–75]. The
evidence for the efficacy of conventional medication in the
treatment of depression, such as tricyclics antidepressants
and selective serotonin reuptake inhibitors, is very limited.
This could be a consequence of their late onset of action.
The use of psychostimulants, which on the contrary grant
for a rather rapid onset of action might, therefore, deserve
more attention [63].
It is thus rather difficult to clearly determine as to what
is the best treatment for major depression disorders (MDD)
in cancer patients. It has been assumed that conventional
evidence-based treatments for depression in noncancer
patients can be applicable [76], although further research is
anyway required. Additional studies on how to treat
depression are also needed to better understand the role of
depression treatments in the improvement of life quality, as
it has been proved they may lead to a higher completion of
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Table 1 Melatonin level and cancer risk
First author Journal and
year





48,725 participants in the
Women’s Health Initiative
Observational Study, among
whom 452 adjudicated incident
cases of endometrial cancer.
7.5 years of follow-up.
Night-shift work is associated
with increased endometrial
cancer risk
Indication of reduced risk









11 years). 525 incident cases of
breast cancer
Sleep duration hypothesized to be
inversely associated with breast
cancer risk
Sleep duration may influence
breast cancer risk, possibly via







Low urinary melatonin levels
have been associated with an
increased risk of breast cancer
in premenopausal women.
Results from this prospective
study provide evidence for a
statistically significant inverse
association between melatonin
levels, as measured in overnight
morning urine, and invasive
breast cancer risk in
postmenopausal women.




127 patients diagnosed with
breast cancer and among 353
control subjects
Experimental data from animals
suggest a protective role for the
pineal hormone melatonin in the
etiology of breast cancer
We found no evidence that the
level of melatonin is strongly
associated with the risk for
breast cancer.




24: 8 young men, 7 elderly
patients with benign prostatic
hyperplasia and nine patients of
similar age with primary
prostate cancer
Depression of serum melatonin in
PC is due to a reduced pineal
activity and is not caused by an
enhanced metabolic degradation
in the liver.
These results imply it is feasible
to estimate changes in pineal
function of prostate cancer
patients by means of non-
invasive determination using
urinary melatonin and aMT6s.
Bartsch C et al.
[36]
Cancer 1991 17 with breast cancer ? 4 with
untreated benign breast disease
Depression of circulating
melatonin in patients with
primary breast cancer must be
due to a reduced activity of the
pineal gland.
The nocturnal melatonin and
6-sulfatoxymelatonin
concentrations were
significantly depressed in the
group of patients with primary
breast cancer compared with
controls (P less than 0.01, P less
than 0.025). The circadian
amplitudes of melatonin and
6-sulfatoxymelatonin were also
depressed by 81 % (P less than




Cancer 1989 35 with breast cancer ? 28 with
untreated benign breast disease
Stage-dependent depression of
melatonin in patients with
primary breast cancer
A 50 % depression of peak and
amplitude occurred in the group
of patients with primary breast
cancer compared with age-
matched controls (P less than
0.001, P less than 0.01). The
peak declined with increasing
tumor size: 27 % at Stage T1,
53 % at T2 (P less than 0.001),
and 73 % at T3 (P less than
0.05). In contrast, patients with
secondary breast cancer,
particularly those receiving
antiestrogen therapy, had a
melatonin peak similar to
controls.
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adjuvant therapy and can actually extend lifetime [72, 77,
78].
Literature does not include recent double-blind placebo-
controlled studies on the use of melatonin in the treatment
of cancer patients’ depression. However, numerous studies
actually prove that melatonin is effective in the treatment
of major depression in adult [79–81] and elderly patients
[21]. In addition the scientific community shows a rising
interest on this topic: in April 2012, a protocol article was
published in the British Medical Journal to present a clin-
ical trial which should shortly be started. Such a double-
blind placebo-controlled trial is to investigate the effect
that melatonin performs on breast cancer patients’
depression, anxiety, sleep, and cognitive function disorders
[82].
With regard to sleep, the risk of insomnia is usually high
in cancer patients [83, 84], yet no large study on the
prevalence and nature of cancer patients’ sleep disturbance
is available to date. The most interesting study on this topic
is that of Davidson et al. [83]. This cross-sectional survey
study examined (a) the prevalence of reported sleep prob-
lems in the patients registered by six clinics at a regional
cancer center, (b) sleep problem prevalence in relation to
cancer treatment, and (c) the nature of reported insomnia
(type, duration, and associated factors). The most prevalent
problems seem to be excessive fatigue (44 % of patients),
leg restlessness (41 %), insomnia (31 %), and excessive
sleepiness (28 %). The breast clinic registered a high
prevalence of insomnia and fatigue. Recent cancer treat-
ment was associated with excessive fatigue and hyper-
somnolence. Insomnia commonly involved multiple
awakenings (76 % of cases) and duration C 6 months
(75 % of cases). In most cases (48 %), insomnia onset was
reported to coincide with time at which cancer was actually
diagnosed (from 6 months pre-diagnosis to 18 months
post-diagnosis).
The causes of cancer patients’ sleep disturbance are
various, numerous, and pre-existing sleep difficulties often
seem to be aggravated by cancer [68].
Cancer itself, including tumors responsible for steroid
production and symptoms of tumor invasion (pain, dysp-
noea, fatigue, nausea, and pruritus) can also contribute to
poor sleep. As a result of chemotherapy, corticosteroid
treatment and hormonal fluctuations also affect patients’
sleep and so do medications (narcotics, chemotherapy,
neuroleptics, sympathomimetics, sedative/hypnotics, ste-
roids, caffeine/nicotine, antidepressants, and diet supple-
ments) and environmental factors (disturbing light and
noise and/or extreme temperature in bedrooms). In addi-
tion, the correlation between insomnia and an increased
psychological distress due to cancer diagnosis, as well as
increased hot flashes caused by menopause, which is often
induced by breast cancer treatment, must also be
investigated [85]. In cancer patients insomnia may lead to
fatigue, mood disturbances, contribute to immunosuppres-
sion, affect life quality, and to some extent, may also
impact on the course of disease [86] too. The most prob-
able hypothesis about the phenomenology of sleep in breast
cancer patients is that the challenges they face may con-
tribute to or cause insomnia, which in turn may exacerbate
cancer-associated medical conditions such as pain, psy-
chiatric comorbidities, fatigue, use of opioids (which could
contribute to daytime sedation and sleep disorder breath-
ing), stimulating or alerting drugs, napping, and preexisting
sleep disturbance [87], thus enhancing a negative feedback
loop.
Few pharmacological studies investigating the effect of
sleeping pills on cancer patients’ insomnia and other
symptoms did not register any significant relevance with
respect to the full symptom cluster. Although numerous
drugs are currently approved for the treatment of insomnia,
to date none of them has been tested for safety or efficacy
in cancer patients [84]. No pharmacological treatment has
been thus specifically validated for the treatment of cancer
cluster symptoms. In a cross-sectional survey carried out in
Israel on more than 900 cancer patients, the use of a
sleeping pill or a tranquilizer was reported by 25 % and
was associated with poorer QOL as well as with increased
severity of symptoms like insomnia, fatigue, pain, dysp-
noea, and constipation. As a conclusion, authors outlined
causal inference is not possible given the cross-sectional
design [88]. This reinforces the need for well-controlled
clinical trials aiming at detecting the best pharmacological
sleep treatments for targeted patients.
With regard to drugs treating insomnia in cancer
patients, a study by Casault et al. [89] recently assessed the
type and frequency of hypnotic medication among a large
sample of randomly selected patients who had been pre-
viously treated for cancer. Overall, hypnotic medication
resulted to be used by 22.6 % out of the patients’s sample.
Factors associated with a larger use of hypnotic medication
were older age, greater difficulty to fall asleep, more
stressful life events experienced over the past 6 months,
higher levels of anxiety, past or current psychological
difficulties, poorer role functioning, less severe urinary
symptoms, larger use of opioids as well as past or current
chemotherapy treatments. In spite of the precautions taken
to ensure that the medication was specifically prescribed
for sleep disturbance, the registered rate of current use
(22.6 %) was very similar to those reported by Davidson
et al. [83] (21.5 %) as well as by Paltiel et al. [88]
(25.7 %), who had not made any distinction between the
use of medication for sleep and the use of anxiolytic
medication or tranquilizers for more general purposes. Also
to be mentioned, the prevalence rate of hypnotic con-
sumption since the cancer diagnosis was 37 % (for both
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current and past users). In this study, nearly 80 % out of the
participants who were to take drugs were prescribed ben-
zodiazepine (mainly lorazepam and oxazepam), followed
by zoplicone (9 %), a non-benzodiazepine hypnotic.
Overall, 12.7 % out of the total sample currently used a
drug different from the prescribed medication to control
sleep disturbance. Moreover, this study showed that three
out of four times hypnotics had been prescribed by general
practitioners. Based on this, it might be concluded that
cancer patients are more inclined to discuss about their
sleeping difficulties with their general practitioner, rather
than with oncologists, maybe because they feel more at
ease, due either to a consolidated relationship of confidence
or to the fact that, compared with oncologists, practioners
normally perform longer and more informal visits. Such a
result is similar to those reported in the epidemiological
study by Morin et al. [90], according to which over the
previous year 15 % out of the sample (2001 participants
from Quebec) had been opting for natural products, 3.8 %
had been using over-the-counter medications, whereas
4.1 % of them had been turning to alcohol to treat
insomnia. Among cancer patients it might be thus assumed
that the consumption rate for substances other than hypn-
otics appears to be equivalent to the rate generally observed
among Quebec’s population. Although sleep experts rec-
ommend patients to limit the use of hypnotics to a period of
2–4 weeks, in this study the average duration turned to be
close to 5 years. Moreover, a large proportion (78 %) of
the sample used it every day. With such an extended and
regular usage, tolerance is very likely; this means that for
many patients medications had a lower effect over the time,
thus leaving them with unrelieved or only partially treated
sleep disturbances (e.g., fatigue and mood disturbances).
To date no double-blind placebo-controlled study has
been performed to investigate the use of melatonin in the
tratment of cancer patients’ sleep disorders.
Melatonin and anticancer effects
This research has been carried out based on the keywords
‘‘melatonin’’ AND ‘‘anticancer’’ OR ‘‘oncostatic’’; 59
articles were sourced: 13 about in vitro studies, 28 about
animal model studies and 18 about clinical studies. With
respect to mood disturbance, the research has been carried
out based on the keywords: ‘‘melatonin’’ AND ‘‘cancer’’
AND ‘‘depression’’ OR ‘‘mood disturbances’’; 99 articles
were sourced. Between these, studies with the greatest
number of patients has been selected and discussed.
Clinical studies in cancer patients show that [91]:
1. melatonin lowers the toxicity of various chemothera-
peutic agents including cisplatin, etoposide, anthracy-
clines, and 5-fluorouracil;
2. in addition, studies registered a statistically significant
reduction in treatment-related adverse events, such as
myelosuppression, neurotoxicity, nephrotoxicity, car-
diotoxicity and asthenia, which overall result in a
decreased mortality rate.
A significantly larger interest for the use of melatonin in
cancer treatment was recently raised by the Journal of
Pineal Research, publishing the meta-analysis performed
by a research group led by Mills et al. [92]. The authors
studied 643 cancer patients that did not respond to con-
ventional therapy between 1992 and 2002. Such patients
were given melatonin as sole treatment for a variety of
different solid tumors including lung, brain, skin, renal, and
breast. The effect of large doses of melatonin (10–40 mg/
day) was assessed on survival rates after 1 year. The risk of
death at 1 year was reduced by 34 %. Effects were con-
sistent depending on melatonin dosage as well as on cancer
type. No severe adverse events were reported and the study
concluded that substantial reduction in death risk, low side
effects, and low costs can actually forecast a larger
potential use of melatonin in cancer treatment.
The role of melatonin as an oncostatic drug has been
widely documented in in vivo and in vitro experimental
investigations, covering a large number of different neo-
plasias including breast, prostate, colorectal cancer, glio-
blastoma, leukemia, etc. [93–99]. This definitely clashes
with the very limited number of clinical trials aiming at
possibly transferring such basic findings into proper clini-
cal protocols [91]. An exhaustive review on anticancer
drugs is provided by Grant et al. [18].
In vitro and in animal model studies
Studies proved melatonin plays a role in the prevention of
tumor initiation, promotion, and progression. Melatonin’s
oncostatic properties relate to
a) its antiproliferative effects [93, 97];
b) direct inducing of natural killer cell activity, which
enhances immunosurveillance and stimulates cytokine
production, such as interleukin 2,6, 12, and interferon
gamma [17];
c) its ability to increase protein 53, a tumor suppressor
protein [100];
d) inhibiting linoleic acid uptake via activation of MT1
and MT2 receptors, thereby preventing the formation
of the mitogenetic metabolite 1,3-hydroxyoctadecadi-
enoic acid [101];
e) its capacity to induce cell differentiation [102];
f) its antimetastatic effects [103];
g) its anti-angiogenic activity [104];
h) its ability to modulate gene expression [105];
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761 pts Solid tumor
cancers
20 mg/die Melatonin as an adjuvant therapy
for cancer led to substantial
improvements in tumor
















Not specified Melatonin reduced the risk of
death at 1 year (relative risk:
0.66, 95 % confidence interval:
0.59–0.73, I2 = 0 %,
heterogeneity P B 0.56).
Effects were consistent across











20 mg/die This preliminary study shows that
the efficacy of weekly low-dose
CPT-11 in pretreated metastatic
colorectal cancer patients may
be enhanced by a concomitant







14 pts Metastatic prostate
cancer
20 mg/die A decrease in PSA serum levels
greater than 50 % was obtained
in 8/14 (57 %) patients, a
survival longer than 1 year was
achieved in 9/14 (64 %)
patients. The concomitant
administration of the pineal
hormone MLT may overcome
clinical resistance to LHRH










Brain glioblastoma 20 mg/die Both the survival curve and the
survival % at 1 year were
significantly higher in patients
treated with RT plus MLT than









40 mg/die This study suggests low-dose
subcutaneous IL-2 plus
melatonin may be effective as a
second-line therapy to induce
tumor regression and to prolong
% survival at 1 year in
metastatic colorectal cancer
patients progressing under 5-FU
and folates.
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i) its interaction with estrogen receptors, down-regulating
their expression, binding to DNA and transactivation
[97, 106, 107];
j) its anti aromatase actions [108, 109];
k) its modulation of the immune response [110, 111];
l) its capacity to decrease telomerase activity [112, 113];
and
m) its function as a free radical scavenger [114].
Studies in animal models generally support the
hypothesis according to which melatonin can influence the
frequency and growth of spontaneous and induced tumors:
a pinealectomy can increase tumorigenesis and shorten
survival time, whereas administration of melatonin rever-
ses these trends and inhibits tumor growth [115].
Clinical studies
Melatonin is transmitted through receptors as well as
through distinct second-messenger pathways to reduce
cellular proliferation and induce cellular differentiation. In
addition, independently from receptors, melatonin can also
modulate estrogen-dependent pathways and reduce free-
radical formation, thus preventing mutation and cellular
toxicity. Since melatonin works through a myriad of cell-
protecting signaling cascades, this hormone can be suitable
for clinical cancer prevention and/or treatment [91].
Wang et al. [116] recent meta-analysis of randomized
controlled trials indicates a consistent effect on tumor
remission, 1-year survival, and radiochemotherapy-related
side effects of adjunct melatonin in a variety of advanced
stage cancers. As an adjuvant therapy melatonin led to
significantly higher tumor remission, better survival at
1 year, and less radiochemotherapy-related side effects,
including thrombocytopenia, neurotoxicity, and fatigue. In
many cases cancer had previously resulted to be refractory
to standard therapy and thus more suitable for the adjunct
use of an untested and unproven therapy like melatonin.
The large efficacy as well as the limited number of serious
adverse events should actually be of interest to both cli-
nicians and patients. The main limitation is that most [6]
trials were performed in the same center [117–122], while
only two other studies were performed in different centers


















14 pts Metastatic breast
cancer
20 mg/die A partial response was achieved
in 4/14 (28.5 %) patients
(median duration 8 months.
The concomitant administration
of the pineal hormone MLT
may induce objective tumor
regressions in metastatic breast









Breast cancer 20 mg/die Partial response rate was
significantly higher in patients
treated with TMX and MLT
than in those, who received
TMX alone (7/19 vs 2/21,
P \ 0.05). Moreover, the
survival % at 1 year was
significantly higher in patients
treated with TMX plus MLT
than in those treated with TMX






Brain metastases 20 mg/die The pineal hormone melatonin
may be able to improve the
survival time and the quality of
life in patients with brain








50 mg/die Objective tumor regressions were
obtained in 5/14 (36 %)
patients.
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trials has been enlarged, it is still relatively limited. Since
such items may to some extent affect the reliability of the
results assessed, authors pointed out international multi-
centre RCTs with larger sample size are still needed. In the
eight studies performed, a once-a-day 20-mg melatonin
oral dosage was prescribed. Table 2 summarizes the main
studies in which melatonin was administered to cancer
patients.
Toxicity studies of melatonin
The vast majority of studies document the very low toxicity
of melatonin over a wide range of doses, even in up to
20-mg dosages, as reported by Sa´nchez-Barcelo´ et al. [91],
where a number of clinical trials have been reviewed to
assess the therapeutic usefulness of melatonin in different
medical fields.
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